|Bid||17.29 x 1200|
|Ask||17.31 x 1000|
|Day's Range||17.05 - 17.39|
|52 Week Range||11.03 - 32.95|
|Beta (3Y Monthly)||2.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.55|
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
Intellia Therapeutics Inc’s (NASDAQ: NTLA ) gene editing drug seems to have the potential to disrupt the treatment of hereditary transthyretin amyloidosis, according to Baird. The Analyst Madhu Kumar initiated ...
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
CAMBRIDGE, Mass., May 30, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc., (NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and joins Intellia to head its drug research organization. Andrew Schiermeier, Ph.D., executive vice president of development and corporate strategy, will continue to lead the drug development organization.
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 7.55% and -14.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA), reported operational highlights and financial results for the first quarter ended March 31, 2019. “2019 is off to a productive start in support of our mission to advance genome editing to treat a range of severe and life-threatening diseases. In particular, we presented data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy showing unprecedented CRISPR-mediated, targeted gene insertion in the liver of non-human primates, achieving normal circulating human levels of protein production,” said Intellia President and Chief Executive Officer John Leonard, M.D. “These achievements highlight Intellia’s leadership in CRISPR/Cas9 genome editing as we advance our pipeline towards the clinic.
Intellia Therapeutics, Inc. (NTLA), will present today new data, including the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates (NHPs), at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019, in Washington, D.C. Researchers also will present today new in vitro data from Intellia’s lead engineered cell therapy program in acute myeloid leukemia (AML). Later this week at the 2019 ASGCT meeting, Intellia will present new data from its primary hyperoxaluria (PH1) program.
CAMBRIDGE, Mass., April 25, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. Warning! GuruFocus has detected 3 Warning Signs with NTLA.
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
CAMBRIDGE, Mass., April 15, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22nd Annual Meeting of the American Society of Gene and.
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
Editas Medicine signed a collaboration deal with oncology player BlueRock Therapeutics on Wednesday — following in the footsteps of other CRISPR gene-editing companies. Editas stock lifted.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that's small comfort given the dismal price performance over theRead More...
Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday. Smoter declined to offer an explanation on how Leonard's name was included in Starboard's slate of five directors to challenge Bristol-Myers' board. Starboard declined to comment.